ACRV Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Acrivon Therapeutics Inc (ACRV) is not a compelling buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks strong positive catalysts, has weak financial performance, and no significant trading signals or trends to support a buy decision. Holding off for now is recommended.
The MACD histogram is below 0 and negatively contracting, indicating bearish momentum. RSI is neutral at 36.418, and moving averages are converging, showing no clear trend. The stock is trading near its support level (S1: 1.505) with resistance at R1: 1.834.
Piper Sandler raised the price target to $8 from $6 and maintained an Overweight rating, citing promising Phase II data and plans for IND submission in Q4 2026.
No recent news or significant trading trends. Financial performance is weak, with declining net income (-18.75% YoY) and EPS (-20.34% YoY). Technical indicators suggest no strong upward momentum. Stock trend analysis predicts a potential decline in the next week (-2.1%) and month (-4.19%).
In Q3 2025, revenue remained at $0 with no growth. Net income dropped to -$18.23M (-18.75% YoY), and EPS fell to -0.47 (-20.34% YoY). Gross margin is 0%. Overall, the financials indicate poor performance and no growth.
Piper Sandler raised the price target to $8 from $6 and maintained an Overweight rating, citing positive Phase II data and future IND submission plans. However, this is a long-term catalyst and does not support immediate action.
